U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C11H17NO3
Molecular Weight 211.258
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ISOPROTERENOL

SMILES

CC(C)NCC(c1ccc(c(c1)O)O)O

InChI

InChIKey=JWZZKOKVBUJMES-UHFFFAOYSA-N
InChI=1S/C11H17NO3/c1-7(2)12-6-11(15)8-3-4-9(13)10(14)5-8/h3-5,7,11-15H,6H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C11H17NO3
Molecular Weight 211.258
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: description was created based on several sources, including https://www.drugs.com/cdi/isoproterenol.html | https://www.ncbi.nlm.nih.gov/pubmed/209581 | https://www.ncbi.nlm.nih.gov/pubmed/22073124 | https://www.ncbi.nlm.nih.gov/pubmed/11723224

Isoproterenol (trade names Medihaler-Iso and Isuprel) is a medication used for the treatment of bradycardia (slow heart rate), heart block, and rarely for asthma. Isoproterenol is a non-selective β adrenoreceptor agonist and TAAR1 agonist that is the isopropylaminomethyl analog of epinephrine. Isoprenaline's effects on the cardiovascular system (non-selective) relate to its actions on cardiac β1 receptors and β2 receptors on smooth muscle within the tunica media of arterioles. Isoprenaline has positive inotropic and chronotropic effects on the heart. β2 adrenoceptor stimulation in arteriolar smooth muscle induces vasodilation. Its inotropic and chronotropic effects elevate systolic blood pressure, while its vasodilatory effects tend to lower diastolic blood pressure. The overall effect is to decrease mean arterial pressure due to the β2 receptors' vasodilation. The adverse effects of isoprenaline are also related to the drug's cardiovascular effects. Isoprenaline can produce tachycardia (an elevated heart rate), which predisposes patients to cardiac arrhythmias.

Originator

Sources: Archiv fuer Experimentelle Pathologie und Pharmakologie, Volume 197, Pages 41-56, Journal, 1940

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ISOPROTERENOL HYDROCHLORIDE

Approved Use

Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.)

Launch Date

-4.35974406E11
Primary
ISOPROTERENOL HYDROCHLORIDE

Approved Use

Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.)

Launch Date

-4.35974406E11
Primary
ISOPROTERENOL HYDROCHLORIDE

Approved Use

Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.)

Launch Date

-4.35974406E11
Primary
ISOPROTERENOL HYDROCHLORIDE

Approved Use

Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.)

Launch Date

-4.35974406E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
42 ng/mL
0.3 mg/kg single, subcutaneous
dose: 0.3 mg/kg
route of administration: Subcutaneous
experiment type: SINGLE
co-administered:
ISOPROTERENOL plasma
Rattus norvegicus
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
15 mg 1 times / day multiple, respiratory (max)
Studied dose
Dose: 15 mg, 1 times / day
Route: respiratory
Route: multiple
Dose: 15 mg, 1 times / day
Sources: Page: p.642
unhealthy, 27 - 67
n = 12
Health Status: unhealthy
Condition: Bronchial asthma
Age Group: 27 - 67
Sex: M+F
Population Size: 12
Sources: Page: p.642
Other AEs: Tachycardia, Premature ventricular contractions...
Other AEs:
Tachycardia (66.7%)
Premature ventricular contractions (8.3%)
Sources: Page: p.642
0.2 mg multiple, intravenous (max)
Recommended
Dose: 0.2 mg
Route: intravenous
Route: multiple
Dose: 0.2 mg
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Heart block|Adams-Stokes attacks|Cardiac arrest
Sources: Page: p.2
Disc. AE: Block heart, Adams-Stokes syndrome...
AEs leading to
discontinuation/dose reduction:
Block heart
Adams-Stokes syndrome
Sources: Page: p.2
1 mg multiple, intramuscular (max)
Recommended
Dose: 1 mg
Route: intramuscular
Route: multiple
Dose: 1 mg
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Heart block|Adams-Stokes attacks|Cardiac arrest
Sources: Page: p.2
Disc. AE: Block heart, Adams-Stokes syndrome...
AEs leading to
discontinuation/dose reduction:
Block heart
Adams-Stokes syndrome
Sources: Page: p.2
AEs

AEs

AESignificanceDosePopulation
Tachycardia 66.7%
15 mg 1 times / day multiple, respiratory (max)
Studied dose
Dose: 15 mg, 1 times / day
Route: respiratory
Route: multiple
Dose: 15 mg, 1 times / day
Sources: Page: p.642
unhealthy, 27 - 67
n = 12
Health Status: unhealthy
Condition: Bronchial asthma
Age Group: 27 - 67
Sex: M+F
Population Size: 12
Sources: Page: p.642
Premature ventricular contractions 8.3%
15 mg 1 times / day multiple, respiratory (max)
Studied dose
Dose: 15 mg, 1 times / day
Route: respiratory
Route: multiple
Dose: 15 mg, 1 times / day
Sources: Page: p.642
unhealthy, 27 - 67
n = 12
Health Status: unhealthy
Condition: Bronchial asthma
Age Group: 27 - 67
Sex: M+F
Population Size: 12
Sources: Page: p.642
Adams-Stokes syndrome Disc. AE
0.2 mg multiple, intravenous (max)
Recommended
Dose: 0.2 mg
Route: intravenous
Route: multiple
Dose: 0.2 mg
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Heart block|Adams-Stokes attacks|Cardiac arrest
Sources: Page: p.2
Block heart Disc. AE
0.2 mg multiple, intravenous (max)
Recommended
Dose: 0.2 mg
Route: intravenous
Route: multiple
Dose: 0.2 mg
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Heart block|Adams-Stokes attacks|Cardiac arrest
Sources: Page: p.2
Adams-Stokes syndrome Disc. AE
1 mg multiple, intramuscular (max)
Recommended
Dose: 1 mg
Route: intramuscular
Route: multiple
Dose: 1 mg
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Heart block|Adams-Stokes attacks|Cardiac arrest
Sources: Page: p.2
Block heart Disc. AE
1 mg multiple, intramuscular (max)
Recommended
Dose: 1 mg
Route: intramuscular
Route: multiple
Dose: 1 mg
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Heart block|Adams-Stokes attacks|Cardiac arrest
Sources: Page: p.2
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as perpetrator​

Drug as perpetrator​

Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
[Myocardial DNA and cell count following isoproterenol-induced myocardial necrosis in the rat].
1975
Method for the production of severe ventricular dysrhythmias in small laboratory animals.
1975
Membrane phospholipid metabolism in the isoproterenol-induced cardiomyopathy of the rat.
1975
Metabolic response after isoproterenol-induced myocardial infarction in arteriosclerotic breeder vs nonarteriosclerotic virgin intact and gonadectomized male rats.
1975 Apr
Serum prolactin levels in rats following isoproterenol-induced myocardial infarction.
1975 Dec
Electrophysiologic studies in the denervated transplanted human heart. II. Response to norepinephrine, isoproterenol and propranolol.
1975 Dec
[Pharmacology of acebutolol in animals].
1975 Dec 31
Prolyl hydroxylase and collagen metabolism after experimental mycardial infarction.
1975 Jan
Effects of prindolol on isoproterenol-induced subendocardial ischaemia in dogs with multiple chronic coronary artery occlusion.
1975 Jul
Metabolic responses following isoproterenol-induced myocardial infarction in arteriosclerotic breeder vs. non-arteriosclerotic virgin and ovariectomized female rats.
1975 May-Jun
[Prevention of isoproterenol-induced lesions in the rat myocardium by prenylamine].
1975 Sep-Oct
Activity of Na+/K+-ATPase and of Ca++-ATPase under the action of adenosine triphosphate in experimental myocardial hypertrophy.
1998 Jul-Dec
Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy.
1999 Nov
Effects of beta-receptor blockade and angiotensin II type I receptor antagonism in isoproterenol-induced heart failure in the rat.
1999 Nov-Dec
Effect of beta(2)-adrenoceptor activation and angiotensin II on tumour necrosis factor and interleukin 6 gene transcription in the rat renal resident macrophage cells.
1999 Oct
In vivo evidence that isoproterenol may increase heart rate in the rat by mechanisms in addition to activation of cardiac beta(1)- or beta(2)-adrenoceptors.
1999 Oct 15
Inhibition of adipocyte lipolysis by papaverine: papaverine can inhibit the redistribution of hormone-sensitive lipase.
2000
Influences of catecholamines on the sudden death induced in dogs by an antifungal agent, D0870.
2000 Apr
Recurrent asystoles associated with vasovagal reaction during venipuncture.
2000 Dec
Viral-mediated gene delivery of constitutively activated G alpha s alters vasoreactivity.
2000 Jan-Feb
Pharmacological effects of an aldehyde type alpha/beta-adrenoceptor blocking agent with vasodilating properties.
2000 Jun
Requirement of activation of the extracellular signal-regulated kinase cascade in myocardial cell hypertrophy.
2000 Jun
Isoproterenol-induced myocardial injury resulting in altered S100A4 and S100A11 protein expression in the rat.
2000 Jun
Hypersensitivity of cerebral artery response to catecholamine in patients with neurally mediated syncope induced by isoproterenol.
2000 Jun 1
Isoproterenol-induced hypertrophy may result in distinct left ventricular changes.
2000 May-Jun
[Effects of isoprenaline on apoptosis related gene expression in rat myocardium cells].
2000 Nov
Catecholamines suppress leptin release from in vitro differentiated subcutaneous human adipocytes in primary culture via beta1- and beta2-adrenergic receptors.
2000 Sep
Coronary microvascular endothelial cells cosecrete angiotensin II and endothelin-1 via a regulated pathway.
2000 Sep
Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction.
2000 Sep
Lipopolysaccharide-induced tumor necrosis factor-alpha release is controlled by the central nervous system.
2001
Evidence that ranolazine behaves as a weak beta1- and beta2-adrenoceptor antagonist in the rat [correction of cat] cardiovascular system.
2001 Apr
A comparison of effects measured with isotonic and isometric recording: II. Concentration-effect curves for physiological antagonists.
2001 Aug
Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system.
2001 Dec
Interaction of calcitonin gene-related peptide (CGRP), substance P (SP) and conventional autonomic agonists in rat submandibular salivary peroxidase release in vitro.
2001 Jan 14
cAMP mediated upregulation of CYP2A5 in mouse hepatocytes.
2001 Jan 26
Different mechanisms of isoproterenol-induced and nitroglycerin-induced syncope during head-up tilt in patients with unexplained syncope: important role of epinephrine in nitroglycerin-induced syncope.
2001 Jul
Catecholamines stimulate interleukin-6 synthesis in rat cardiac fibroblasts.
2001 Jul
Alterative and plastic insufficiency of cardiomyocytes: isoproterenol-induced damage to myocardium during anthracycline cardiomyopathy.
2001 Jun
Neurohormonal regulation of secretion from isolated rat stomach ECL cells: a critical reappraisal.
2001 Mar 2
PKC-beta is not necessary for cardiac hypertrophy.
2001 May
In vitro activity of polyhydroxycarboxylates against herpesviruses and HIV.
2001 Nov
Calcineurin-GATA4 pathway is involved in beta-adrenergic agonist-responsive endothelin-1 transcription in cardiac myocytes.
2001 Sep 14
Impaired intracellular signal transduction via cyclic AMP contributes to cerebral vasospasm in rats with subarachnoid hemorrhage.
2002 Apr
Expression of human angiotensinogen-renin in rat: effects on transcription and heart function.
2002 Feb
The regulation of human vascular smooth muscle extracellular matrix protein production by alpha- and beta-adrenoceptor stimulation.
2002 Feb
99mTc-glucarate for detection of isoproterenol-induced myocardial infarction in rats.
2002 Feb 21
Synergistic effect of nicorandil and amlodipine on mitochondrial function during isoproterenol-induced myocardial infarction in rats.
2002 Jan
Bone marrow-derived regenerated cardiomyocytes (CMG Cells) express functional adrenergic and muscarinic receptors.
2002 Jan 22
Glucose uptake via SGLT-1 is stimulated by beta(2)-adrenoceptors in the ruminal epithelium of sheep.
2002 Jun
Vanillylamide-based propanolamine derivative displays alpha/beta-adrenoceptor blocking and vasodilating properties.
2002 Jun
Patents

Sample Use Guides

Bolus intravenous injection: 0.02 mg to 0.06 mg; Intravenous infusion: 5 mcg/min; Intramuscular 0.2 mg; Subcutaneous 0.2 mg; Intracardiac 0.02 mg;
Route of Administration: Other
Human embryonic kidney cells (HEK293) were cultured in Minimum Essential Medium (MEM) Earle’s (Biochrom AG) supplemented with 10% FBS (PAA Laboratories GmbH), 100 U/ml penicillin, and 100 mg/ml streptomycin (Biochrom AG) and 2 mM L-glutamine (Invitrogen) at 37C with 5% CO2. 48 well plates were coated with Poly-L-Lysine (Biochrom) and HEK293 cells were seeded with 37,500 cells per well. Transient transfection in triplicates with 84 ng DNA/well using metafectene according to manufactures instructions (Biontex, Munich, Germany) was performed 28 hours later. 40 hours after transfection cells were pre-incubated for 5 minutes with stimulation buffer containing of MEM Earle’s media and 1 mM 3-isobutyl-1-methylxanthine (IBMX, Sigma). This stimulation buffer was used for all further steps. For ligand competition experiments cells were incubated with tyramine, 2-phenylethylamine or octopamine ranging from 6.7 nM to 6700 nM, diluted in stimulation buffer for 15 minutes followed by a stimulation with isoprenaline in concentrations ranging from 1 nM to 10000 nM for 30 minutes. All reactions were performed at 37C with 5% CO2 saturated air and stopped by aspirating medium.
Substance Class Chemical
Created
by admin
on Sat Jun 26 10:00:52 UTC 2021
Edited
by admin
on Sat Jun 26 10:00:52 UTC 2021
Record UNII
L628TT009W
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ISOPROTERENOL
MI   VANDF  
Common Name English
ALEUDRIN
Brand Name English
ISOPRENALINE
INN   MART.   WHO-DD  
INN  
Official Name English
ASSIPRENOL
Brand Name English
ISOPROTERENOL [MI]
Common Name English
ISORENIN
Brand Name English
ISOPRENALINE [MART.]
Common Name English
ISONORIN
Brand Name English
NEO-EPININE
Brand Name English
ISOPRENALINE [WHO-DD]
Common Name English
ISOPROTERENOL DL-FORM [MI]
Common Name English
RESPIFRAL
Brand Name English
BELLASTHMAN
Brand Name English
ALUDRINE
Brand Name English
ISOPROTERENOL [VANDF]
Common Name English
NSC-9975
Code English
ASIPRENOL
Brand Name English
1,2-BENZENEDIOL, 4-(1-HYDROXY-2-((1-METHYLETHYL)AMINO)ETHYL)-
Systematic Name English
SAVENTRINE
Brand Name English
NOVODRIN
Brand Name English
3,4-DIHYDROXY-.ALPHA.-((ISOPROPYLAMINO)METHYL)BENZYL ALCOHOL
Systematic Name English
PROTERNOL
Brand Name English
ISOPROPYDRIN
Brand Name English
ISOPRENALINE [INN]
Common Name English
ASMALAR
Brand Name English
VAPO-N-ISO
Brand Name English
NSC-33791
Code English
NEODRENAL
Brand Name English
ISUPREN
Brand Name English
A-21
Code English
Classification Tree Code System Code
WHO-VATC QC01CA02
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
NCI_THESAURUS C319
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
WHO-ATC C01CA02
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
WHO-ATC R03AK02
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
NDF-RT N0000175555
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
NDF-RT N0000000245
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
WHO-ATC R03CB01
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
WHO-ATC R03AB02
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
WHO-VATC QR03AB02
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
WHO-VATC QR03CB01
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
WHO-VATC QR03AK02
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
WHO-VATC QR03CB51
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
WHO-ATC R03CB51
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
Code System Code Type Description
ChEMBL
CHEMBL434
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
PRIMARY
MESH
D007545
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
PRIMARY
DRUG CENTRAL
1499
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
PRIMARY
WIKIPEDIA
ISOPRENALINE
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
PRIMARY
CAS
7683-59-2
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
PRIMARY
DRUG BANK
DB01064
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
PRIMARY
PUBCHEM
3779
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
PRIMARY
MERCK INDEX
M6533
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
PRIMARY Merck Index
FDA UNII
L628TT009W
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
PRIMARY
RXCUI
6054
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
PRIMARY RxNorm
IUPHAR
536
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
PRIMARY
EVMPD
SUB08330MIG
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
PRIMARY
EPA CompTox
7683-59-2
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
PRIMARY
MERCK INDEX
M6533
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
231-687-7
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
PRIMARY
NCI_THESAURUS
C62041
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
PRIMARY
INN
4201
Created by admin on Sat Jun 26 10:00:53 UTC 2021 , Edited by admin on Sat Jun 26 10:00:53 UTC 2021
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
SHORT-ACTING
TARGET -> AGONIST
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
TARGET -> AGONIST
SHORT-ACTING
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY